Annmarie Louise Sabb
Princeton University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Annmarie Louise Sabb.
Journal of Pharmacology and Experimental Therapeutics | 2006
Karen L. Marquis; Annmarie Louise Sabb; Sheree F. Logue; Michael Piesla; Tom A. Comery; Steven M. Grauer; Charles R. Ashby; Huy Quang Nguyen; Lee A. Dawson; James E. Barrett; Gary Paul Stack; Herbert Y. Meltzer; Boyd L. Harrison; Sharon Rosenzweig-Lipson
Serotonin-2C (5-HT2C) receptor antagonists and agonists have been shown to affect dopamine (DA) neurotransmission, with agonists selectively decreasing mesolimbic DA. As antipsychotic efficacy is proposed to be associated with decreased mesolimbic DA neurotransmission by virtue of DA D2 receptor antagonism, the 5-HT2C-selective receptor agonist, WAY-163909 [(7bR,10aR)-1,2, 3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7, 1hi]indole], was evaluated in animal models of schizophrenia and in vivo microdialysis and electrophysiology to determine the effects on mesolimbic and nigrostriatal DA neurotransmission. Similar to clozapine, WAY-163909 (1.7–30 mg/kg i.p.) decreased apomorphine-induced climbing with little effect on stereotypy and no significant induction of catalepsy. WAY-163909 (0.3–3 mg/kg s.c.) more potently reduced phencyclidine-induced locomotor activity compared with d-amphetamine with no effect on spontaneous activity. WAY-163909 (1.7–17 mg/kg i.p.) reversed MK-801 (5H-dibenzo[a,d]cyclohepten-5,10-imine (dizocilpine maleate)- and DOI [1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane]-disrupted prepulse inhibition of startle (PPI) and improved PPI in DBA/2N mice. In conditioned avoidance responding, WAY-163909 (0.3–3 mg/kg i.p.; 1–17 mg/kg p.o.) reduced avoidance responding, an effect blocked by the 5-HT2B/2C receptor antagonist SB 206553 [5-methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole]. WAY-163909 (10 mg/kg s.c.) selectively decreased extracellular levels of DA in the nucleus accumbens without affecting the striatum. Likewise, in vivo electrophysiological recordings showed a decrease in the number of spontaneously firing DA neurons in the ventral tegmental area but not in the substantia nigra with both acute and chronic (21-day) administration of WAY-163909 (1–10 mg/kg i.p.). Thus, the profile of the 5-HT2C selective receptor agonist WAY-163909 is similar to that of an atypical antipsychotic and additionally may have rapid onset properties.
Brain Research | 2006
Sharon Rosenzweig-Lipson; Jean Zhang; Hossein Mazandarani; Boyd L. Harrison; Annmarie Louise Sabb; Joan Eileen Sabalski; Gary Stack; Greg Welmaker; James E. Barrett; John Dunlop
WAY-161503 ((4aR)-8,9-dichloro-2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)-one), a 5-HT(2B/C) receptor agonist, was characterized in vitro using stable Chinese hamster ovary cell lines expressing each of the human 5-HT2 receptors and in vivo in animal models of obesity. WAY-161503 displaced both agonist ([125I]2,5-dimethoxy-4-iodoamphetamine (DOI)) and antagonist ([3H]mesulergine) radioligand binding to the human 5-HT2C receptor with derived Ki values of 3.3 +/- 0.9 and 32 +/- 6 nM, respectively. Relative to 5-HT2C receptor binding, WAY-161503 was approximately 6-fold less potent at human 5-HT2A receptors ([125I]DOI) with a derived Ki value of 18 nM and 20-fold less potent at human 5-HT2B receptors ([3H]5-HT) with a derived Ki value of 60 nM. In functional studies, WAY-161503 was a full agonist in stimulating 5-HT2C-receptor-coupled [3H]inositol phosphate (IP) formation and calcium mobilization with EC50 values of 8.5 nM and 0.8 nM, respectively. WAY-161503 was also a 5-HT2B agonist (EC50s of 6.9 and 1.8 nM for IP and calcium, respectively). In IP studies, WAY-161503 was a weak 5-HT(2A) partial agonist (EC50, 802 nM) yet potently stimulated calcium mobilization (EC50, 7 nM) in 5-HT2A receptor-expressing cells. Functionally, WAY-161503 also stimulated the phospholipase A2-coupled arachidonic acid release in 5-HT2C receptor expressing cells albeit with lower potency (EC50, 38 nM) and efficacy (Emax, 77%) compared with activation of the PLC pathway. In vivo, WAY-161503 produced dose-dependent decreases in 2-h food intake in 24 h fasted normal Sprague-Dawley rats, diet-induced obese mice, and obese Zuker rats with ED50 values of 1.9 mg/kg, 6.8 mg/kg, and 0.73 mg/kg, respectively. The reduction in food intake in normal Sprague-Dawley rats was reversed by administration of the 5-HT2C receptor antagonist SB-242084. Following chronic administration (10 days) in growing Sprague-Dawley rats, WAY-161503 decreased food intake and attenuated body weight gain. Finally, following chronic administration (15 days) of WAY-161503 to obese Zuker rats, the rats maintained a 30% decrease in food intake over the 15-day period combined with a 25 g decrease in body weight relative to vehicle-treated controls demonstrating a lack of tolerance to its anorectic effects.
Bioorganic & Medicinal Chemistry Letters | 2000
Gregory Scott Welmaker; James Albert Nelson; Joan Eileen Sabalski; Annmarie Louise Sabb; John R. Potoski; Denise Graziano; Michael Z. Kagan; Joseph Coupet; John Dunlop; Hossein Mazandarani; Sharon Rosenzweig-Lipson; Stacey J. Sukoff; Yingxin Zhang
A series of 2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5-(6H)ones and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxalines was shown to exhibit 5-HT2C agonist binding and functional activity. Compound 21R inhibited food intake over 2 h in fasted, male Sprague Dawley rats with ED50 values of 2 mg/kg (i.p.) and 10 mg/kg (p.o.).
Journal of Medicinal Chemistry | 2010
Wayne E. Childers; Lisa Marie Havran; Magda Asselin; James Jacob Bicksler; Dan C. Chong; George Theodore Grosu; Zhongqi Shen; A. Abou-Gharbia Magid; Alvin C. Bach; Boyd L. Harrison; Natasha Kagan; Teresa Kleintop; Ronald L. Magolda; Vasilios Marathias; Albert Jean Robichaud; Annmarie Louise Sabb; Mei-Yi Zhang; Terrance H. Andree; Susan H. Aschmies; Chad E. Beyer; Thomas A. Comery; Mark L. Day; Steven M. Grauer; Zoe A. Hughes; Sharon Rosenzweig-Lipson; Brian Platt; Claudine Pulicicchio; Deborah E. Smith; Stacy J. Sukoff-Rizzo; Kelly Sullivan
As part of an effort to identify 5-HT(1A) antagonists that did not possess typical arylalkylamine or keto/amido-alkyl aryl piperazine scaffolds, prototype compound 10a was identified from earlier work in a combined 5-HT(1A) antagonist/SSRI program. This quinolyl-piperazinyl piperidine analogue displayed potent, selective 5-HT(1A) antagonism but suffered from poor oxidative metabolic stability, resulting in low exposure following oral administration. SAR studies, driven primarily by in vitro liver microsomal stability assessment, identified compound 10b, which displayed improved oral bioavailability and lower intrinsic clearance. Further changes to the scaffold (e.g., 10r) resulted in a loss in potency. Compound 10b displayed cognitive enhancing effects in a number of animal models of learning and memory, enhanced the antidepressant-like effects of the SSRI fluoxetine, and reversed the sexual dysfunction induced by chronic fluoxetine treatment.
Bioorganic & Medicinal Chemistry Letters | 1999
Annmarie Louise Sabb; G. E. Morris Husbands; Joseph Tokolics; Reinhardt P. Stein; Rene Tasse; Carl A. Boast; John A. Moyer; Magid Abou-Gharbia
Rational drug design utilizing a receptor homology model of the human muscarinic M1 receptor led to the discovery of the highly potent (Ki = 2 nM), efficacious, and in vivo functionally-selective M1 agonist, WAY-132983.
Synthetic Communications | 1984
Edward C. Taylor; Stephen R. Fletcher; Annmarie Louise Sabb
Abstract A convenient one-pot synthesis of t-butyl p-aminobenzoate is described which involves treatment of p-aminobenzoic acid with thionyl chloride, followed by reaction of the resulting p-sulfinylaminobenzoyl chloride with t-butanol.
Bioorganic & Medicinal Chemistry Letters | 2001
Annmarie Louise Sabb; Robert Lewis Vogel; Michael G. Kelly; Yvette Latko Palmer; Deborah L. Smith; Terrance H. Andree; Lee E. Schechter
Amino acid derivatives of 1,2,5-thiadiazol-3-yl-piperazine related to (+)-WAY-100135 and WAY-100635 are potent 5-HT1A receptor agonists and antagonists, which have selective affinity for 5-HT1A receptors versus alpha1 and dopamine (D2, D3, and D4) receptors.
Drug Development Research | 1997
Annmarie Louise Sabb; Reinhardt P. Stein; Robert Lewis Vogel; Rene Tasse; Susan Amburn; Denise Fairman; Dianne Kowal; Deepa Malhotra; Carl A. Boast; Adam C. Bartolomeo; Herman Morris; Tracy Sailer; John A. Moyer; Magid Abou-Gharbia; Douglas M. Ho
Computer modeling of carbachol docked in the human m1 receptor binding pocket has been used to discover a series of carbamate and thiocarbamate chiral, conformationally restricted analogues of carbachol based on azabicyclo[2.2.1]heptan‐3‐ol. These molecules have been evaluated for affinity and efficacy at human muscarinic receptors (m1–m5) transfected into a CHO cell line. None of these compounds was selective in binding. Thiocarbamate analogues had greater affinity for the m1 receptor subtype, but lower efficacy based on comparison of their ability to induce phosphoinositide (PI) turnover. Carbamate analogues had lower affinity for m1 receptors than thiocarbamates and varied in efficacy from 10% to 100% of the carbachol response in phosphoinositide (PI) turnover. One of these analogues 3S,4R‐azabicyclo[2.2.1]heptan‐3‐methylcarbamate, WAY‐131256, (VI) has been characterized as an m1/m2 agonist in vitro. (VI) was equi‐efficacious to the standard m1 agonist, xanomeline (Phase III) in vivo in a scopolamine‐impaired radial arm maze paradigm (MED 1 mg/kg, 5.88 mmol/kg for VI and MED 1 mg/kg, 3.55 mmoles/kg for xanomeline) and was approximately equal to xanomeline in an AF64A‐impaired radial arm maze paradigm. Despite its lack of m1 selectivity in vitro, in vivo experiments on (VI) indicated no significant effect on blood pressure or heart rate at 10 mg/kg (58.78 mmol/kg) (i.p.), and no peripheral side effects attributed to stimulation of either the m2 or m3 receptors (salivation, lacrimation, and chromodacryorrhea) up to doses of 30 mg/kg, 176.2 mmol/kg. These results may be explained by different receptor densities in various brain regions not accounted for in a transfected cell line or by metabolism of (VI) to a m1 selective agonist in vivo. Drug Dev. Res. 40:185–192, 1997.
Journal of Pharmacology and Experimental Therapeutics | 2004
John Dunlop; Annmarie Louise Sabb; Hossein Mazandarani; Jean Zhang; Sachin Kalgaonker; Eugenia Shukhina; Stacey J. Sukoff; Robert Lewis Vogel; Gary Paul Stack; Lee E. Schechter; Boyd L. Harrison; Sharon Rosenzweig-Lipson
Psychopharmacology | 2007
Sharon Rosenzweig-Lipson; Annmarie Louise Sabb; Gary Paul Stack; Paul J. Mitchell; Irwin Lucki; Jessica Malberg; Steve Grauer; John F. Cryan; Stacey J. Sukoff Rizzo; John Dunlop; James E. Barrett; Karen L. Marquis